Products
Precemtabart Biosimilar Monoclonal Antibody (CEA) for Research
Cat No.: GMP-Bios-INN-1347
Anti-CEACAM5/CD66e therapeutic antibody (Pre-made Precemtabart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Precemtabart (development code M9140) is a monoclonal antibody targeting CEACAM5 (CEA). It is developed by Merck KGaA and EMD Serono Research & Development Institute for Colorectal cancer in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1347-1mg | 1mg | 3090 |
| GMP-Bios-INN-1347-10mg | 10mg | |
| GMP-Bios-INN-1347-100mg | 100mg | |
| GMP-Bios-INN-1347-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Precemtabart biosimilar, Whole mAb, Anti-CEACAM5/CD66e Antibody: Anti-CD66e/CEA therapeutic antibody |
| INN Name | Precemtabart |
| Target | CEACAM5/CD66e |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Merck KGaA;EMD Serono Research & Development Institute |
| Conditions Approved | na |
| Conditions Active | Colorectal cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
